ArticleClinical cancer research : an official journal of the American Association for Cancer Research2011

Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies.

Mayer N Fishman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.